Krystal Biotech (KRYS) Net Income towards Common Stockholders (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Net Income towards Common Stockholders data on file, last reported at $55.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 56.56% year-over-year to $55.9 million; the trailing twelve-month figure through Mar 2026 stood at $225.1 million (up 81.59% YoY), and the FY2025 full-year result was $204.8 million, up 129.74% from the prior year.
• Net Income towards Common Stockholders grew to $55.9 million in Q1 2026, from $51.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $80.7 million in Q3 2023 to a low of -$114.3 million in Q1 2023.
• A 5-year average of $3.0 million and a median of $15.6 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders plunged 173.27% in 2022 and soared 3734.01% in 2025, its largest moves.
• Tracing KRYS's Net Income towards Common Stockholders over 5 years: stood at -$34.0 million in 2022, then soared by 125.55% to $8.7 million in 2023, then jumped by 423.23% to $45.5 million in 2024, then grew by 13.0% to $51.4 million in 2025, then rose by 8.86% to $55.9 million in 2026.
• Business Quant data shows KRYS's Net Income towards Common Stockholders at $55.9 million in Q1 2026, $51.4 million in Q4 2025, and $79.4 million in Q3 2025.